Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor | Zendy

Senthilkumar Alagesan | Zendy; Matthew D. Griffin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor

Author(s) -

Senthilkumar Alagesan,

Matthew D. Griffin

Publication year - 2014

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2013.405

Subject(s) - macrophage , kidney disease , kidney , medicine , macrophage colony stimulating factor , ex vivo , peripheral blood mononuclear cell , bone marrow , immunology , nephropathy , immune system , population , cytokine , in vivo , inflammation , cancer research , biology , in vitro , endocrinology , microbiology and biotechnology , biochemistry , environmental health , diabetes mellitus

Infusing ex vivo-generated alternatively activated macrophages (AAM) has shown promise in experimental systems as a therapeutic strategy for inflammatory kidney disease. In the mouse Adriamycin nephropathy model, however, Cao et al. report that AAM derived from bone marrow precursors fail to ameliorate disease severity. Absence of the anticipated protective effect resulted from a loss of macrophage anti-inflammatory (M2) phenotype following trafficking to injured kidney-an effect that was mediated by localized colony-stimulating factor-1-dependent macrophage proliferation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research